Somerville, MA, United States of America

Julien Papillon

This inventor holds 26 USPTO granted patents and 9 published patent applications, plus 3 CIPO patents and 14 EPO patents, primarily in Organic Compounds. Top assignees: Novartis Ag, Bausch + Lomb Ireland Limited. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Julien Papillon. Retrieved from https://idiyas.com/inventor/julien-papillon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 9)

% Patents Active = 61.5

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 14 (Patent Applications = 20)

Average Co-Inventor Count = 4.0

ph-index = 4

Forward Citations = 45(Granted Patents)

Location History:

Cambridge, MA (US) (2013)
Somerville, MA (US) (2011 - 2024)

Company Filing History:

Bausch + Lomb Ireland Limited

patents

where one patent can have more than one assignee

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

AZA-Quinoline Compounds

Quinoline Inhibitors

Cyclobutyl Derivatives

SMARCA2 Inhibitors

Protein Kinase C

Adrenal Hormone Agents

Aryl Pyridine

Aldosterone Synthase

Benzoxazolone Derivatives

Organic Chemistry

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12544374 - AZA-quinoline compounds and uses thereof (2026-02-10),

2. 12473273 - Quinoline compounds and compositions for inhibiting EZH2 (2025-11-18),

3. 12435040 - 1,3-substituted cyclobutyl derivatives and uses thereof (2025-10-07),

4. 12358906 - Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors (2025-07-15),

5. 11958846 - Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors (2024-04-16),

6. 11845730 - 1,3-substituted cyclobutyl derivatives and uses thereof (2023-12-19),

7. 11505541 - Protein kinase C inhibitors and methods of their use (2022-11-22),

8. 11059804 - Protein kinase C inhibitors and methods of their use (2021-07-13),

9. 10508101 - Protein kinase C inhibitors and methods of their use (2019-12-17),

10. 9845309 - Protein kinase C inhibitors and methods of their use (2017-12-19),

11. 9452998 - Protein kinase C inhibitors and methods of their use (2016-09-27),

12. 9434754 - Use of an adrenal hormone-modifying agent (2016-09-06),

13. 9278969 - Organic compounds (2016-03-08),

14. 9242963 - Organic compounds (2016-01-26),

15. 8835646 - Organic compounds (2014-09-16),

Title: Innovations and Contributions of Julien Papillon

Introduction

Julien Papillon, based in Somerville, MA, is an accomplished inventor with an impressive portfolio of 22 patents. His work primarily focuses on developing compounds and compositions that serve as innovative therapies for various diseases and disorders.

Latest Patents

Among his latest patents, one significant innovation includes "Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors." This patent presents a compound of Formula (I) or a pharmaceutically acceptable salt that has shown promise in treating BRM-mediated and/or BRG1-mediated diseases. Another notable patent is for "1,3-substituted cyclobutyl derivatives and uses thereof," which outlines compounds and pharmaceutical compositions effective in treating conditions mediated by the TRPV1 receptor. This invention also details methods for addressing ocular diseases through therapeutically effective amounts of the compounds described.

Career Highlights

Julien Papillon has made substantial contributions to the field of pharmaceutical research while working at Novartis AG. His expertise and innovative approaches have garnered recognition in the industry, reflecting his commitment to advancing therapeutic options for patients.

Collaborations

Throughout his career, Julien has collaborated with esteemed colleagues such as Qi-Ying Hu and Gary Michael Ksander. These partnerships have fostered the development of groundbreaking innovations and have been integral in amplifying the impact of his research.

Conclusion

Julien Papillon's contributions to patent innovation underscore his dedication to improving healthcare solutions. His extensive experience and notable patents position him as a leading figure in the field, continuing to influence the trajectory of medical therapies.

Profile summary based on public USPTO records.